A Vision for the Future of Science Philanthropy
By Evan S. Michelson and Adam F. Falk,
Issues in Science and Technology
| 11. 09. 2021
Although we can envision many ways that the scientific enterprise might evolve in the future, an often-overlooked component will surely play an essential role: science philanthropy. By this we mean the provision of charitable giving for science or technology research by individual donors or foundations. As Robert Conn, past president and chief executive officer of The Kavli Foundation, details in his overview of the emergence of philanthropic giving for research, science philanthropy has always played a critical and leading role in America’s approach to research and development, with a history that predates much of the federal funding apparatus.
Today, the landscape of science philanthropy is rapidly changing. It consists of both established and newer foundations, a constellation of institutions including organizations with an illustrious history of giving for research as well as entities created more recently. Collectively, science philanthropy accounts for at least $2 billion in annual support for research. If we include spending from university endowments that supports research at those institutions, the total impact of philanthropy on science is estimated to be as much as $20 billion per...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...